Conclusions
high-grade glioma
In conclusion, this dose-escalation phase I study demonstrated that the injectable form of CGA was well tolerated in patients with recurrent high-grade glioma. Preliminary anti-tumor activities, and potentially OS benefits for these heavily pre-treated patients, were observed. Deeper responses to CGA monotherapy may be investigated and confirmed in a phase 2 clinical trial.